Multiple Endocrine Neoplasia type 2 (MEN2) and RET  Genetics Home Reference

Initial release: June 2008
Last update: January 2020

MEN2 is an inherited, autosomal dominant disorder consisting of three syndromes: MEN2A, MEN2B, and Familial Medullary Thyroid Carcinoma (FMTC). These syndromes result in a high lifetime risk of developing medullary thyroid carcinoma, due to mutations within the RET proto-oncogene.

The aim of the MEN2 RET database is to record all RET sequence changes relevant to the MEN2 syndromes, as well as any associated clinical information and pertinent literature references. This database will serve as a repository for MEN2-associated RET sequence variation and a reference for RET genotype/MEN2 phenotype correlations.

RET genotypes were generated using the Human Genome Variation Society sequence variation nomenclature and reference sequences NC_000010.9 and NM_020975.5. The MEN2 phenotype definitions used in the database were derived from the International RET Mutation Consortium guidelines for classification of MEN2 disease phenotypes.

ARUP Laboratories offers the following testing:
  • RET exons 5, 8, 10, 11, and 13-16 (test 0051390)
  • Single exon sequencing for a previously identified familial RET mutation (upon request).

Database Information

The RET database currently has 199 total entries.


When citing in publications please use:

Margraf RL, Crockett DK, Krautscheid P, Seamons R, Calderon FR, Wittwer CT, Mao R. The Multiple Endocrine Neoplasia type 2 RET proto-oncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat. 2009 Apr;30(4):548-56.

Database URL: